Data is critical to all value-based care, said Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
Data is critical to all value-based care, said Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
Transcript
How important is the availability of data analytics to be able to compare how a provider or health system compares with others and to learn best practices?
Data is critical to all value-based care. If you can’t know what your outcomes are, then you can’t test, and if you can’t test, you can’t improve. So, you have to have core data to do that work. I think it’s important to remember that all data is wrong. As you engage with clinicians, really showing them here’s what we see in the data, what does it mean to you, and you glean a lot more information from it and iterate on it. I think without the data, how do you know that you’re improving? How do you know what your baseline is? And, how do you know where you have variation? So, we’ve got to have the data.
I think what’s new in thinking is that the data’s no longer your clinical data. You have to think about your pharmacy data, your fill data for pharmacy. You have to think about social determinants, and there’s so much data on those aspects that you can combine those together in a way to give you new insights.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More